Sevelamer Carbonate Tablet
Product Images NDC 11788-116

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 11788-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aiping Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (800mg 270)

Label for Sevelamer Carbonate Tablets 800 mg by AiPing Pharmaceutical, Inc. The package contains 270 film-coated tablets for oral use. The label includes storage instructions and states the tablets each contain 800 mg of Sevelamer carbonate. The labeler and manufacturing location in Hauppauge, NY are also noted.*

FDA Label Image

Figure-1 (Fig 1)

Chemical structure diagram of sevelamer carbonate, showing polymeric repeating units with ammonium, bicarbonate, amine, and hydroxyl functional groups.*

FDA Label Image

Figure-2 (Fig 2)

A forest plot chart depicting subgroup analyses of treatment effects comparing Sevelamer Carbonate versus placebo. The x-axis represents the treatment effect difference with a scale from -5 to 5 favoring Sevelamer Carbonate to placebo, respectively. Various subgroups are listed on the y-axis, including overall, screening body surface area (BSA), baseline serum phosphorus levels, age groups, and dialysis status. Data points with confidence intervals are shown for each subgroup, along with sample sizes, least squares mean differences, and 95% confidence intervals.*

FDA Label Image

Figure-3 (Fig 3)

A line graph showing the percentage of patients with reduction in serum phosphorus (mg/dL) over a range from -4 to 8. Two lines compare Sevelamer Hydrochloride and an Active Control in terms of their effect on serum phosphorus reduction from baseline, indicating patient response patterns from worsened increase to improved reduction.*

FDA Label Image

Figure-4 (Fig 4)

A line chart depicting phosphorus change from baseline over a 52-week study period. The x-axis represents study weeks from 0 to 52, and the y-axis shows phosphorus change from baseline ranging from -5 to 2. Two treatment groups are plotted: Sevelamer Hydrochloride (black circles) and Active-Control (red squares). Both show a decrease in phosphorus levels initially, stabilizing between -2 and -3 after around 10 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.